| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
A Phase 1 clinical trial led by the University of California San Francisco (UCSF) assessing research partner Filament Health Corp.’s (OTCQB:FLHLF) botanical psychedelic drug candidates has shown positive interim outcomes.
See also: San Francisco: Psychedelics Finally Decriminalized, Here's The New Resolution
The UCSF’s Translational Psychedelic Research Program (TrPR) administered a total of fifteen doses of the company’s naturally-sourced psilocybin (PEX010) as well as naturally-sourced psilocin (PEX020 and PEX030,) to four healthy subjects, reporting good tolerability and no serious or unexpected adverse events.
Filament is a clinical-stage natural psychedelic drug development company aiming to standardize naturally-derived psychedelic medicines.
See also: EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill
The company has stated that this is the first FDA-approved clinical trial of a naturally-derived psychedelic drug candidate and the first time psilocin has been directly administered in a clinical trial.
TrPR director and study PI Dr. Joshua Woolley added that “these are the first reported clinical trial results regarding a naturally sourced psychedelic drug.” He added that considering the drug candidates have been well-tolerated, the study will continue as planned.
Filament CEO and co-founder Benjamin Lightburn says the company is proud to continue its relationship with UCSF and “to have such promising early results.”
“This industry-first trial is a testament to Filament’s innovative drug development and operational capabilities,” Lightburn concluded.
Photo: Benzinga edit with photo by Sisacorn and Bizi88 on Shutterstock.
Posted In: FLHLF
